Insight Molecular Diagnostics Inc.
IMDXDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
How IMDX's past catalysts played out
99mTc-MIP-1404 Injection
Prostate Cancer
Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Dry Eye
UltratraceTM Iobenguane I 131 Imaging
Neuroblastoma
Iodofiltic acid I 123
Acute Coronary Syndrome
Ultratrace Iobenguane (MIBG) I 131
Pheochromocytoma
NeuVax vaccine
Breast Cancer
Drug: 99mTc-MIP-1404
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
99mTc-MIP-1404 Injection | Phase 3 | Prostate Cancer | - | - |
Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free | Phase 3 | Dry Eye | - | - |
UltratraceTM Iobenguane I 131 Imaging | Phase 2 | Neuroblastoma | - | - |
Iodofiltic acid I 123 | Phase 2 | Acute Coronary Syndrome | - | - |
Ultratrace Iobenguane (MIBG) I 131 | Phase 2 | Pheochromocytoma | - | - |
NeuVax vaccine | Phase 2 | Breast Cancer | - | - |
Drug: 99mTc-MIP-1404 | Phase 2 | Prostate Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Insight Molecular Diagnostics Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Insight Molecular Diagnostics Inc.'s (IMDX) pipeline across Phase 3, Phase 2. Its lead program is 99mTc-MIP-1404 Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Insight Molecular Diagnostics Inc.'s next FDA catalyst?→
Insight Molecular Diagnostics Inc.'s (IMDX) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMDX biotech catalysts?→
Add IMDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Insight Molecular Diagnostics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.